Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

LLM 2021 | Preventing progression to ATLL in HTLV-1 carriers

Adrienne Phillips • 26 Oct 2021
LLM 2021
Lymphoma T-Cell Lymphoma

Adrienne Phillips, MD, Weill Cornell Medicine, New York, NY, discusses the importance of developing methods to prevent human T-cell leukemia virus type I (HTLV-1) carriers from progressing to adult T-cell leukemia/lymphoma (ATLL). Dr Phillips highlights novel methods using HTLV-1 proviral load monitoring to identify patients at risk of progression to ATL. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.

More from Adrienne Phillips

1:20
Limitations of CAR T-cell therapy for DLBCL
Adrienne Phillips • 26 Oct 2021
0:48
LLM lymphoma highlights: ATLL
Adrienne Phillips • 26 Oct 2021
1:51
Current treatments and new developments for adult ATLL
Adrienne Phillips • 26 Oct 2021

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals